Your browser doesn't support javascript.
loading
Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma.
Ghandour, Rashed A; Freifeld, Yuval; Cheaib, Joseph; Singla, Nirmish; Meng, Xiaosong; Kenigsberg, Alexander; Bagrodia, Aditya; Woldu, Solomon; Hoffman-Censits, Jean; Enikeev, Dmitry; Rapoport, Leonid; Petros, Firas G; Raman, Jay D; Pierorazio, Philip M; Matin, Surena F; Margulis, Vitaly.
Afiliación
  • Ghandour RA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH. Electronic address: vitaly.margulis@utsouthwestern.edu.
  • Freifeld Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Cheaib J; The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Singla N; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Meng X; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Kenigsberg A; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Bagrodia A; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Woldu S; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Hoffman-Censits J; The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD.
  • Enikeev D; Institute for Urology and Reproductive Health, Sechenov University, Moscow.
  • Rapoport L; Institute for Urology and Reproductive Health, Sechenov University, Moscow.
  • Petros FG; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Raman JD; Division of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA.
  • Pierorazio PM; The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Matin SF; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Margulis V; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Institute for Urology and Reproductive Health, Sechenov University, Moscow.
Urol Oncol ; 39(11): 788.e15-788.e21, 2021 11.
Article en En | MEDLINE | ID: mdl-34330655
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Cisplatino / Terapia Neoadyuvante / Nefroureterectomía / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Urol Oncol Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Cisplatino / Terapia Neoadyuvante / Nefroureterectomía / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Urol Oncol Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2021 Tipo del documento: Article